HCPCS Q4115 is officially defined as "Alloskin, per square centimeter (add-on, list separately in addition to primary procedure)." HCPCS Q4115 is referenced in 8 tracked payer policy changes from Sentara Health Plans, Humana, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q4115 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Starting January 1, 2027, Sentara Health Plans will require prior authorization for a long list of codes on Virginia commercial plans, including self-funded (ASO) plans, and for code 88380 on commercial, Medicaid and Medicare products, plus code 22860 on Medicare products. Sentara will also stop covering a separate list of codes on Virginia commercial and self-funded plans.
Humana's revised Kentucky Medicaid policy on skin and tissue substitutes lists the only covered uses as diabetic foot ulcers and venous leg ulcers that have lasted more than 4 weeks, when standard wound care criteria are met, and states that prior authorization is required. The policy lists many HCPCS codes for these products as requiring prior authorization for Humana Healthy Horizons members in Kentucky. The source gives an effective date of 08/12/2026, and the code list in the provided text is cut off near the end.
The Arkansas Department of Human Services will require prior authorization for the skin substitute procedures listed in the notice, after the HHS Office of Inspector General flagged skin substitutes as a major area for fraud, waste and abuse. The listed HCPCS codes require prior authorization for dates of service beginning 6/1/2026, and each listed code carries modifier SG. A prior authorization may be requested through AFMC using process type 112 (Other Medical Service).
Health Net California is updating prior authorization requirements effective December 1, 2025, removing PA requirements for many DME items, prosthetics, sleep studies, varicose vein treatments, and therapy services while maintaining PA requirements for non-emergency air transport, hysterectomies, and skin substitutes. These changes aim to reduce administrative burden and streamline approval processes.
Michigan Medicaid has revised its policy for skin and tissue substitutes, effective June 5, 2026. Coverage is limited to specific diabetic foot ulcers and chronic venous leg ulcers over 4 weeks duration when used with comprehensive standard wound therapy, with strict documentation requirements for all criteria.
New Medicaid policy in Illinois establishes coverage criteria for skin and tissue substitutes for diabetic foot ulcers and chronic venous leg ulcers when specific medical conditions are met. The policy lists covered HCPCS codes and requires comprehensive wound care protocols including standard therapies, infection management, and appropriate clinical assessments.
Aetna's Clinical Policy Bulletin 0244 sets the coverage rules for skin and soft tissue substitutes used on chronic wounds. Aetna considers these products medically necessary for chronic wounds that failed to respond to treatment when the member is 18 or older, is a non-smoker or has completed or is enrolled in smoking cessation therapy, and the wound is a partial- or full-thickness skin defect of at least 1 cm2 that has not improved after at least four weeks of standard wound care. Diabetic foot ulcers, venous leg ulcers and partial- or full-thickness burn wounds have additional criteria, each listed product has its own indications, and pressure ulcer treatment and other uses are considered not medically necessary, experimental, investigational or unproven.
Several listed tissue-engineered skin substitutes may be considered medically necessary for specific uses, including breast reconstruction with listed acellular dermal matrix products, chronic noninfected full-thickness diabetic lower-extremity ulcers, chronic venous insufficiency ulcers that have not adequately responded to a 1-month period of conventional ulcer therapy, dystrophic epidermolysis bullosa, and second- and third-degree burns. All other uses of the listed products, and all other skin and soft tissue substitutes not listed, are considered investigational. Code reference updates dated 07/01/2026, 08/15/2026 and 10/01/2026 add CPT 1045T through 1049T, HCPCS C9353 and C9361, and HCPCS A2046, A2047, A2048 and A2050 as investigational codes.
Watch Q4115
Get one email when a payer policy names Q4115, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for Q4115
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for Q4115 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.